RadNet (NASDAQ: RDNT) reported Q2 EPS of $0.11, $0.07 better than the analyst estimate of $0.04. Revenue for the quarter came in at $230 million versus the consensus estimate of $231.75 million.

• RadNet reports record Revenue and EBITDA performance
• Total Net Revenue increased 5.2% to $230.0 million in the second quarter of 2017 from $218.6 million in the second quarter of 2016
• Adjusted EBITDA(1) increased 5.5% to $37.0 million in the second quarter of 2017 from $35.1 million in the second quarter of 2016
• Earnings Per Share was $0.11 per share in the second quarter of 2017, an increase from $0.08 from the second quarter of 2016
• Aggregate procedural volumes increased 1.9% (adjusting for the sale of Rhode Island) and same center volumes increased 2.4% as compared with the second quarter of 2016
• RadNet completed the acquisition of its largest free standing outpatient competitor in Delaware, Diagnostic Imaging Associates
• RadNet is launching a refinancing transaction to simplify the capital structure, decrease its cost of debt and lengthen maturities
• RadNet reaffirms previously announced 2017 guidance levels

GUIDANCE:

RadNet sees FY2017 revenue of $895-925 million, versus the consensus of $926.98 million.

For earnings history and earnings-related data on RadNet (RDNT) click here.